Concentra Announces Preliminary Q4 2024 Revenue Of $465M, Up 5.5%, Net Income $20.6M-$22.6M; FY24 Revenue $1.9B, Up 3.4%, Net Income $169.7M-$171.7M; Q4 Adjusted EBITDA Up 13.6% To $77.5M; FY Adjusted EBITDA Up 4.3% To $376.9M; Patient Visits Down 2.1%; CapEx $18.1M In Q4

Benzinga

01-23

Fourth Quarter and Full Year 2024 Preliminary Results

For the fourth quarter 2024, Concentra expects to report:

Revenue of $465.0 million, an increase of 5.5% over Q4 2023
Net income in the range of $20.6 million to $22.6 million, compared to $28.9 million in Q4 2023
Adjusted EBITDA of $77.5 million, an increase of 13.6% over Q4 2023
Patient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in Visits per Day of 2.1% from Q4 2023
Revenue per Visit of $145.08, an increase of 5.8% over Q4 2023
Capital Expenditures of $18.1 million, compared to $23.6 million in Q4 2023
Total occupational health centers of 552, compared to 544 at end of Q4 2023
Total onsite health clinics of 157, compared to 150 at end of Q4 2023

For full year 2024, Concentra expects to report:

Revenue of $1,900.2 million, an increase of 3.4% over FY 2023
Net income in the range of $169.7 million to $171.7 million, compared to $184.7 million in FY 2023
Adjusted EBITDA of $376.9 million, an increase of 4.3% over FY 2023
Cash balance of $183.3 million and net leverage ratio of approximately 3.5x
Patient Visits of 12,623,503, or 49,311 Visits per Day in the quarter, a decrease in Visits per Day of 2.0% from FY 2023
Revenue per Visit of $141.30, an increase of 4.5% over FY 2023
Capital Expenditures of $65.7 million, compared to $65.0 million in FY 2023

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2505472701"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505472701\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2505472701?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 05:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505472701","market":"hk","top_or_hot":-1,"title":"Concentra Announces Preliminary Q4 2024 Revenue Of $465M, Up 5.5%, Net Income $20.6M-$22.6M; FY24 Revenue $1.9B, Up 3.4%, Net Income $169.7M-$171.7M; Q4 Adjusted EBITDA Up 13.6% To $77.5M; FY Adjusted EBITDA Up 4.3% To $376.9M; Patient Visits Down 2.1%; CapEx $18.1M In Q4","media":"Benzinga","content":"<html><body><p><strong>Fourth Quarter and Full Year 2024 Preliminary Results</strong></p><p>For the fourth quarter 2024, Concentra expects to report:</p><ul><li>Revenue of $465.0 million, an increase of 5.5% over Q4 2023</li><li>Net income in the range of $20.6 million to $22.6 million, compared to $28.9 million in Q4 2023</li><li>Adjusted EBITDA of $77.5 million, an increase of 13.6% over Q4 2023</li><li>Patient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in Visits per Day of 2.1% from Q4 2023</li><li>Revenue per Visit of $145.08, an increase of 5.8% over Q4 2023</li><li>Capital Expenditures of $18.1 million, compared to $23.6 million in Q4 2023</li><li>Total occupational health centers of 552, compared to 544 at end of Q4 2023</li><li>Total onsite health clinics of 157, compared to 150 at end of Q4 2023</li></ul><p>For full year 2024, Concentra expects to report:</p><ul><li>Revenue of $1,900.2 million, an increase of 3.4% over FY 2023</li><li>Net income in the range of $169.7 million to $171.7 million, compared to $184.7 million in FY 2023</li><li>Adjusted EBITDA of $376.9 million, an increase of 4.3% over FY 2023</li><li>Cash balance of $183.3 million and net leverage ratio of approximately 3.5x</li><li>Patient Visits of 12,623,503, or 49,311 Visits per Day in the quarter, a decrease in Visits per Day of 2.0% from FY 2023</li><li>Revenue per Visit of $141.30, an increase of 4.5% over FY 2023</li><li>Capital Expenditures of $65.7 million, compared to $65.0 million in FY 2023</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Concentra Announces Preliminary Q4 2024 Revenue Of $465M, Up 5.5%, Net Income $20.6M-$22.6M; FY24 Revenue $1.9B, Up 3.4%, Net Income $169.7M-$171.7M; Q4 Adjusted EBITDA Up 13.6% To $77.5M; FY Adjusted EBITDA Up 4.3% To $376.9M; Patient Visits Down 2.1%; CapEx $18.1M In Q4</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConcentra Announces Preliminary Q4 2024 Revenue Of $465M, Up 5.5%, Net Income $20.6M-$22.6M; FY24 Revenue $1.9B, Up 3.4%, Net Income $169.7M-$171.7M; Q4 Adjusted EBITDA Up 13.6% To $77.5M; FY Adjusted EBITDA Up 4.3% To $376.9M; Patient Visits Down 2.1%; CapEx $18.1M In Q4\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2025-01-23 05:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>Fourth Quarter and Full Year 2024 Preliminary Results</strong></p><p>For the fourth quarter 2024, Concentra expects to report:</p><ul><li>Revenue of $465.0 million, an increase of 5.5% over Q4 2023</li><li>Net income in the range of $20.6 million to $22.6 million, compared to $28.9 million in Q4 2023</li><li>Adjusted EBITDA of $77.5 million, an increase of 13.6% over Q4 2023</li><li>Patient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in Visits per Day of 2.1% from Q4 2023</li><li>Revenue per Visit of $145.08, an increase of 5.8% over Q4 2023</li><li>Capital Expenditures of $18.1 million, compared to $23.6 million in Q4 2023</li><li>Total occupational health centers of 552, compared to 544 at end of Q4 2023</li><li>Total onsite health clinics of 157, compared to 150 at end of Q4 2023</li></ul><p>For full year 2024, Concentra expects to report:</p><ul><li>Revenue of $1,900.2 million, an increase of 3.4% over FY 2023</li><li>Net income in the range of $169.7 million to $171.7 million, compared to $184.7 million in FY 2023</li><li>Adjusted EBITDA of $376.9 million, an increase of 4.3% over FY 2023</li><li>Cash balance of $183.3 million and net leverage ratio of approximately 3.5x</li><li>Patient Visits of 12,623,503, or 49,311 Visits per Day in the quarter, a decrease in Visits per Day of 2.0% from FY 2023</li><li>Revenue per Visit of $141.30, an increase of 4.5% over FY 2023</li><li>Capital Expenditures of $65.7 million, compared to $65.0 million in FY 2023</li></ul></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.benzinga.com/news/earnings/25/01/43146282/concentra-announces-preliminary-q4-2024-revenue-of-465m-up-5-5-net-income-20-6m-22-6m-fy24-revenue-","article_id":"2505472701","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505472701","pubTimestamp":1737582684,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Fourth Quarter and Full Year 2024 Preliminary ResultsFor the fourth quarter 2024, Concentra expects to report:Revenue of $465.0 million, an increase of 5.5% over Q4 2023Net income in the range of $20.6 million to $22.6","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Concentra宣布2024年第四季度初步收入为4.65亿美元，增长5.5%，净利润为2060万至2260万美元；2024财年收入$1.9 B，增长3.4%，净利润$1.697亿-$1.717亿；第四季度调整后EBITDA增长13.6%至7750万美元；财年调整后EBITDA增长4.3%至3.769亿美元；患者就诊量下降2.1%；第四季度资本支出1810万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CON":0.9},"content_text":"Fourth Quarter and Full Year 2024 Preliminary ResultsFor the fourth quarter 2024, Concentra expects to report:Revenue of $465.0 million, an increase of 5.5% over Q4 2023Net income in the range of $20.6 million to $22.6 million, compared to $28.9 million in Q4 2023Adjusted EBITDA of $77.5 million, an increase of 13.6% over Q4 2023Patient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in Visits per Day of 2.1% from Q4 2023Revenue per Visit of $145.08, an increase of 5.8% over Q4 2023Capital Expenditures of $18.1 million, compared to $23.6 million in Q4 2023Total occupational health centers of 552, compared to 544 at end of Q4 2023Total onsite health clinics of 157, compared to 150 at end of Q4 2023For full year 2024, Concentra expects to report:Revenue of $1,900.2 million, an increase of 3.4% over FY 2023Net income in the range of $169.7 million to $171.7 million, compared to $184.7 million in FY 2023Adjusted EBITDA of $376.9 million, an increase of 4.3% over FY 2023Cash balance of $183.3 million and net leverage ratio of approximately 3.5xPatient Visits of 12,623,503, or 49,311 Visits per Day in the quarter, a decrease in Visits per Day of 2.0% from FY 2023Revenue per Visit of $141.30, an increase of 4.5% over FY 2023Capital Expenditures of $65.7 million, compared to $65.0 million in FY 2023","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}